Apricus Bio Wins Third FDA Clearance, Aethlon to Test Blood Filtering Device, & More San Diego Life Sciences News
There wasn’t a lot of news out of San Diego’s life sciences community over the past week, unless you count the executives at public companies who plan to give presentations at various financial conferences in coming weeks. We’ve got the best of the rest, and our briefing begins now.
—San Diego’s Apricus Biosciences (NASDAQ: APRI) says its NexMed subsidiary won FDA clearance for its third over-the-counter topical cream, a reformulated version of diphenhydramine hydrochloride and zinc acetate used to treat itching from insect bites, poison ivy, and other skin irritations. As with the company’s first two drug approvals, NexMed reformulated an existing treatment with a proprietary compound that helps increase skin absorption.
—Luke has recruited an incredible cast of life sciences futurists and genomics experts to discuss “Computing in the Age of the $1,000 Genome,” including Hugh Martin, the CEO of Pacific Biosciences, and Complete Genomics CEO Cliff Reid. Helping Luke moderate will be a few other all-stars, author and Wired magazine executive editor Thomas Goetz, and David Ewing Duncan, the author and Fortune.com columnist. Xconomy is holding the afternoon event on Oct. 24 at the Byers Auditorium on UC San Francisco’s Mission Bay campus. While that might seem a bit far to go, Luke says Illumina CIO Scott Kahn attended a similar event he held last February in Seattle.
—San Diego-based Aethlon Medical said it has arranged a series of tests at the Sarcoma Oncology Center in Santa Monica, CA, to study the effectiveness of its Hemopurifier blood filtration device in removing exosomes from the blood of advanced-stage cancer patients. The company says exosomes released by cancer have emerged as a novel therapeutic target in cancer, as they have been implicated in cancer survival, growth, and metastasis.